Integration of tumor characteristics with breast cancer index
AssigneeBiotheranostics, Inc.
InventorsYi Zhang, Catherine A. Schnabel
Life of this patent
Estimating the term…
Abstract
Methods of determining risk of recurrence of a breast cancer of a subject are provided. Also provided are methods of predicting responsiveness to a therapy of a breast cancer of a subject. Additionally, methods of recommending treatment for a subject that has breast cancer are provided. Further provided are methods of treating a subject that has breast cancer. Systems for performing described methods are also provided.
Claims20
A method of treating breast cancer of a subject who is lymph node-positive, the method comprising
- (i) determining that the subject has an MGIN+ score above an MGIN+ score cut point by:
- assaying or having assayed a sample of breast cancer cells from the subject for the expression levels of BUB1B, CENPA, NEK2, RACGAP1 and RRM2;
- summing or having summed the expression levels of BUB1B, CENPA, NEK2, RACGAP1 and RRM2 as a single index into a subject's MGI index;
- determining or having determined one or more clinicopathological factor selected from tumor size and grade of the subject's breast cancer;
- calculating or having calculated the MGIN+ score of the subject by combining the subject's MGI index with the one or more clinicopathological factor of the subject using a multivariate Cox-proportional model;
- comparing or having compared the subject's MGIN+ score to the MGIN+ score cut point, wherein the MGIN+ score cut point has been pre-determined based on the MGIN+ scores calculated for a training set of samples containing breast cancer tissues from patients who had breast cancer recurrence and patients who did not have breast cancer recurrence;
- and
- (ii) treating the subject with an MGIN+ score above the MGIN+ cut point with chemotherapy or endocrine therapy.
A method of treating breast cancer of a subject who is lymph node-positive, the method comprising
- (i) determining that the subject has an MGIN+ score above 7 by:
- assaying or having assayed a sample of breast cancer cells from the subject for the expression levels of BUB1B, CENPA, NEK2, RACGAP1 and RRM2;
- summing or having summed the expression levels of BUB1B, CENPA, NEK2, RACGAP1 and RRM2 as a single index into a subject's MGI index;
- determining or having determined one or more clinicopathological factor selected from tumor size and grade of the subject's breast cancer;
- calculating or having calculated the MGIN+ score of the subject by combining the subject's MGI index with the one or more clinicopathological factor of the subject using a multivariate Cox-proportional model;
- and
- (ii) treating the subject with an MGIN+ score above 7 with chemotherapy or endocrine therapy.
A method of treating breast cancer of a subject who is lymph node-positive, the method comprising
- (i) determining that the subject has an MGIN+score above an MGIN+score cut point by:
- assaying or having assayed a sample of breast cancer cells from the subject for the expression levels of BUB1B, CENPA, NEK2, RACGAP1 and RRM2;
- summing or having summed the expression levels of BUB1B, CENPA, NEK2, RACGAP1 and RRM2 as a single index into a subject's MGI index;
- determining or having determined one or more clinicopathological factor selected from tumor size and grade of the subject's breast cancer;
- calculating or having calculated the MGIN+ score of the subject by combining the subject's MGI index with the one or more clinicopathological factor of the subject using a multivariate Cox-proportional model;
- comparing or having compared the subject's MGIN+ score to the MGIN+ score cut point, wherein the MGIN+ score cut point has been pre-determined based on the MGIN+ scores calculated for a training set of samples containing breast cancer tissues from patients who were responsive to endocrine therapy and patients who were not responsive to endocrine therapy;
- and
- (ii) treating the subject with an MGIN+ score above the MGIN+ cut point with endocrine therapy.
Dependencies are inferred from the claim text.